Dermata Therapeutics (DRMA) and Revance Therapeutics (RVNC) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.
The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.
Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.
Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.
Price: 3.65, Change: -0.04, Percent Change: -0.95
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。